Juvenile Idiopathic Arthritis
📧 Sign up to get email alerts when something new happens for Juvenile Idiopathic Arthritis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-24EMA Authorised: Yuflyma (adalimumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Yuflyma (adalimumab) for multiple inflammatory diseases including rheumatoid arthritis and Crohn's disease.
-
EMA approval · 2026-08-21EMA Authorised: Tuyory — Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)
EMA authorised Tuyory from Chemical Works of Gedeon Richter Plc. for multiple indications including rheumatoid arthritis, juvenile arthritis…
-
EMA approval · 2026-08-19EMA Authorised: Tyenne (tocilizumab) — Fresenius Kabi Deutschland GmbH
Tyenne (tocilizumab) has been authorised by the EMA for multiple indications including rheumatoid arthritis, cytokine release syndrome, juve…
-
EMA approval · 2026-08-18EMA Authorised: Amgevita (adalimumab) — Amgen Europe B.V.
Amgevita (adalimumab) by Amgen Europe B.V. has been authorised by the EMA for multiple inflammatory diseases including arthritis, psoriatic …
-
EMA approval · 2026-08-13EMA Authorised: RoActemra (tocilizumab) — Roche Registration GmbH
RoActemra (tocilizumab) has been authorised by the European Medicines Agency for multiple indications including rheumatoid arthritis, juveni…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-08-06EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
European Medicines Agency authorises Idacio (adalimumab) from Fresenius Kabi Deutschland for multiple inflammatory diseases including rheuma…
-
EMA approval · 2026-08-05EMA Authorised: Humira (adalimumab) — AbbVie Deutschland GmbH & Co. KG
EMA authorises Humira (adalimumab) for multiple inflammatory diseases across indications, confirming market authorization.
-
EMA approval · 2026-07-21EMA Authorised: Gobivaz (golimumab) — Advanz Pharma Limited
Authorised status for Gobivaz (golimumab) by Advanz Pharma Limited for multiple inflammatory diseases, expanding label in Europe.
-
EMA approval · 2026-07-17EMA Authorised: Hukyndra (adalimumab) — Stada Arzneimittel AG
EU authorization of Hukyndra (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases including rheumatoid arthritis and inf…
-
EMA approval · 2026-07-13EMA Authorised: Libmyris (adalimumab) — Stada Arzneimittel AG
Authorised status for Libmyris (adalimumab) by Stada Arzneimittel AG for multiple inflammatory and autoimmune diseases.
-
EMA approval · 2026-07-13EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
European Medicines Agency authorises Idacio (adalimumab) for multiple inflammatory diseases, expanding the portfolio under Fresenius Kabi De…
-
EMA approval · 2026-07-01EMA Authorised: Gotenfia (golimumab) — Stada Arzneimittel AG
European Medicines Agency authorised Gotenfia (golimumab) by Stada Arzneimittel AG for multiple inflammatory diseases including various form…
-
EMA approval · 2026-06-15EMA Authorised: Tuyory — Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)
Tuyory has been authorised by the EMA for multiple indications including rheumatoid arthritis, juvenile arthritis, cytokine release syndrome…
-
EMA approval · 2026-06-12EMA Authorised: Fubelv — Biosimilar Collaborations Ireland Limited
EMA has authorised Fubelv as a biosimilar, with indications across various inflammatory arthritis and psoriasis conditions.
-
EMA approval · 2026-06-05EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
The EMA has authorised Idacio (adalimumab) by Fresenius Kabi Deutschland GmbH for multiple inflammatory diseases, marking a new approved pro…
-
EMA approval · 2026-04-23EMA Authorised: Taltz (ixekizumab) — Eli Lilly and Company (Ireland) Limited
EMA authorised Taltz (ixekizumab) from Eli Lilly for psoriasis, psoriatic arthritis, axial spondyloarthritis, and juvenile idiopathic arthri…
-
EMA approval · 2026-04-23EMA Authorised: Amgevita (adalimumab) — Amgen Europe B.V.
EMA has authorised Amgevita (adalimumab) by Amgen Europe B.V., a biosimilar of adalimumab, for multiple inflammatory diseases including rheu…
-
EMA approval · 2026-04-01EMA Authorised: RoActemra (tocilizumab) — Roche Registration GmbH
EMA authorised RoActemra (tocilizumab) for multiple indications, including rheumatoid arthritis, juvenile idiopathic arthritis, cytokine rel…
-
EMA approval · 2026-03-19EMA Authorised: Libmyris (adalimumab) — Stada Arzneimittel AG
EMA authorised Libmyris (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases, expanding treatment options in rheumatoid …
-
EMA approval · 2026-02-25EMA Authorised: Gotenfia (golimumab) — Stada Arzneimittel AG
The EMA authorised Gotenfia (golimumab) by Stada Arzneimittel AG for multiple inflammatory diseases, including rheumatoid arthritis, juvenil…
-
EMA approval · 2026-02-16EMA Authorised: Hefiya (adalimumab) — Sandoz GmbH
EMA authorised Hefiya, a biosimilar adalimumab from Sandoz GmbH, for multiple inflammatory conditions including ankylosing spondylitis, hidr…
-
EMA approval · 2026-02-05EMA Authorised: Tocilizumab STADA (previously Tofidence) (tocilizumab) — STADA Arzneimittel AG
EMA authorised STADA's tocilizumab product (Tocilizumab STADA) for rheumatoid arthritis, juvenile idiopathic arthritis, and COVID-19 infecti…
-
EMA approval · 2026-01-28EMA Authorised: Hukyndra (adalimumab) — Stada Arzneimittel AG
EMA authorised Hukyndra (adalimumab) from Stada Arzneimittel AG for multiple inflammatory diseases, including rheumatoid arthritis, psoriati…
-
EMA approval · 2026-01-26EMA Authorised: Avtozma (tocilizumab) — Celltrion Healthcare Hungary Kft.
EMA has authorized Avtozma, a tocilizumab biosimilar, for rheumatoid arthritis, juvenile idiopathic arthritis, cytokine release syndrome, an…
-
FDA approval · 2026-01-14FDA Approved: AVTOZMA — Supplemental Application (CELLTRION USA, Inc.)
FDA approves a supplemental application for AVTOZMA (tocilizumab) filed by Celltrion USA, Inc.